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The reasons for the cellular specificity and slow progression of
motoneuron diseases such as ALS are still poorly understood. We
previously described a motoneuron-specific cell death pathway
downstream of the Fas death receptor, in which synthesis of nitric
oxide (NO) is an obligate step. Motoneurons from ALS model mice
expressing mutant SOD1 showed increased susceptibility to exog-
enous NO as compared with controls. Here, we report a signaling
mechanism whereby NO leads to death of mutant, but not control,
motoneurons. Unexpectedly, exogenous NO triggers expression of
Fas ligand (FasL) in cultured motoneurons. In mutant SOD1G93A and
SOD1G85R, but not in control motoneurons, this up-regulation
results in activation of Fas, leading through Daxx to phosphory-
lation of p38 and further NO synthesis. This FasNO feedback
amplification loop is required for motoneuron death in vitro. In
vivo, mutant SOD1G93A and SOD1G85R mice show increased num-
bers of positive motoneurons and Daxx nuclear bodies weeks
before disease onset. Moreover, FasL up-regulation is reduced in
the presence of transgenic dominant-negative Daxx. We propose
that chronic low-level activation of the FasNO feedback loop may
underlie the motoneuron loss that characterizes familial ALS and
may help to explain its slowly progressive nature.
cell death  motoneuron disease  NO  p38 kinase  neurodegeneration
Amyotrophic lateral sclerosis (ALS) is the most frequent adult-onset motoneuron disease in humans. ALS is characterized by
the selective degeneration of motoneurons in spinal cord, brain-
stem, and cerebral cortex leading to muscle atrophy and paralysis
and ultimately to death. About 1 to 2%of all humanALS forms are
caused by dominantly inheritedmutations in theCuZn superoxide
dismutase (SOD1) gene.Mice transgenic for theALS-linked SOD1
mutations G37R (1), H46RH48Q (2), G85R (3), and G93A (4)
develop an adult-onset motoneuron disorder that remarkably re-
sembles human ALS.
Despitemuch intensive study,many questions remain concerning
the mechanism(s) by which mutant SOD1 triggers specific mo-
toneuron death. One unresolved issue is the cellular site of action
of the gain-of-function mutations. Clement et al. (5) generated
chimeric mice carrying a mixture of WT and mutant SOD1-
expressing cells in the spinal cord. In these mice, WTmotoneurons
eventually showed stigmata of degeneration, whereas some mutant
SOD1 motoneurons were protected from degeneration when sur-
rounded by WT nonneuronal cells. These results suggest that
mutant SOD1 in bothmotoneurons and surrounding cells may play
a role in the disease process.
Our earlier studies using cultures of purified embryonic mo-
toneurons reached similar conclusions. We found that motoneu-
rons from SOD1G93A, SOD1G37R, and SOD1G85R mice survived
normally in the presence of optimal trophic support or when
challenged by excitotoxic agonists. In marked contrast, compared
with controls, they displayed a 10- to 100-fold increase in sensitivity
to extracellular agonists of the Fas receptor or to exogenous nitric
oxide (6). Thus, motoneurons expressing mutant SOD1 have an
intrinsic susceptibility that is only revealed when challenged with
specific extrinsic agents. Only motoneurons, and no other cell type
from mutant SOD1 mice, showed enhanced susceptibility. In
motoneurons, we showed that the Fas receptor signals through two
synergistic pathways involving FaddCaspase-8 and DaxxAsk1
p38nNOS, respectively (6).
Another open question in ALS relates to the kinetics of the
neurodegenerative process. Mutant SOD1 mice display multiple
features of programmed cell death at presymptomatic stages.
Examples are proteolytic activation of caspases-1, -3, -7, -8, and -9
in the spinal cord (7–9),mitochondrial release of cytochrome c (10),
and translocation of Bax from the cytosol to mitochondria (11).
These modifications are manifest weeks to months before there is
significant loss of motoneuron cell bodies or axons. One aspect of
Fas-triggered motoneuron death seemed relevant to these slow
kinetics. Whereas Fas activation in vitro kills lymphocytes within
hours, motoneuron death in the same conditions takes days (12).
The first aim of this study was therefore to identify the molecular
mechanisms that underlie this exceptionally protracted cell death.
Our results linking Fas signaling to mutant SOD1 were
obtained by using purified motoneurons in vitro. A second
important aim of this study was therefore to investigate the
significance of this signaling pathway in mutant SOD1 mice in
vivo. Since our earlier publication (6), other groups studying
mutant SOD1 mice have reported activation of certain inter-
mediates in the Fas pathway we described. In the spinal cord of
SOD1G93A mice, Tortarolo et al. (13), Hu et al. (14), and
Ackerley et al. (15) observed increased p38 activation, whereas
Wengenack et al. (16) reported increased levels of Ask1. How-
ever, these results concern intermediates that are common to
several signaling mechanisms. We therefore focused our atten-
tion on Fas and Daxx, which are specific to this pathway.
We report here that nitric oxide (NO), an end-product of the Fas
pathway in motoneurons, unexpectedly induces expression of the
endogenous Fas ligand (FasL), which in mutant SOD1 motoneu-
rons then triggers further chronic activation of the pathway down-
stream of Fas. This feedback loop is necessary for motoneuron
death induced by NO or FasL in vitro. Furthermore, because all
elements of this feedback loop show perturbed expression in
mutant SOD1mice at presymptomatic stages, it is possible that this
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pathway is linked to the slowly progressive nature of motoneuron
loss in vivo.
Results
Identification of a FasNO Feedback Loop in Mutant SOD1 Motoneu-
rons. Because purified mutant SOD1 motoneurons show increased
susceptibility to activation of the Fas death pathway, we asked
whether expression of key signaling molecules differed between
mutant SOD1 and control mice. Levels of Fas receptor and Fas
ligand (FasL) were estimated by Western blotting. Levels of Fas
were similar between C57BL6 and mutant SOD1 motoneurons
and unchanged by the presence of NO donors such as Detanonoate
{Z-1-[2-(2-aminoethyl)-N-(2-aminonioethyl)amino]diazen-1-ium-
1,2-diolate} (data not shown). The levels of the 38-kDa form of
FasL (17), however, were increased 10- to 15-fold within 6–12 h of
addition of Detanonoate (20 M) to cultures of SOD1G85R and
SOD1G93A motoneurons (Fig. 1 A and B). FasL was up-regulated
to a similar degree in motoneurons from C57BL6 mice (Fig. 1C),
indicating that this eventwas independent of the presence ofmutant
SOD1. FasL up-regulation was concentration-dependent in the
range from 0 to 20 M Detanonoate and motoneuron-specific
(Figs. 6A–D and 7A, which are published as supporting information
on the PNAS web site). FasL up-regulation was also observed after
addition of the NO donor sodium nitroprusside (Fig. 6E). FasL can
exist in bothmembrane-bound and soluble forms (18).However, by
using a sensitiveELISAassay (detection limit 3.6 pgml), no soluble
FasL could be detected in media conditioned by Detanonoate-
treated motoneurons. This result suggests that the FasL expressed
after NO exposure is mostly membrane-bound, and thereforemore
likely to exert autocrine than paracrine effects under these exper-
imental conditions.
We next asked whether the up-regulated FasL was capable of
activating the Fas receptor expressed on the samemotoneurons. As
a reporter for Fas activation, we quantified phosphorylation of p38
kinase, a key event in the Fas pathway in culturedmotoneurons (6),
by immunolabeling of phospho-p38 (Tyr-180Tyr-182) followed by
quantitative confocal microscopy. Phospho-p38 was only weakly
detected in untreated motoneurons, irrespective of the genotype
(mutant SOD1, SOD1WT, or nontransgenic). However, in mutant
SOD1 motoneurons treated with 20 M Detanonoate, phospho-
p38 kinase became clearly apparent in the nucleus and cytoplasm
(Fig. 1D). Quantitative image analysis demonstrated that, after
treatment with Detanonoate, immunoreactivity for phospho-p38
kinase increased by 2- and 2.8-fold in SOD1G93A and SOD1G85R
motoneurons, respectively (P  0.0005; Fig. 1E). In contrast,
identical treatment of control motoneurons from C57BL6 or
SOD1WT mice gave no significant increase in p38 activation
(Fig. 1E).
To confirm that p38 kinase activation was a result of FasL
up-regulation, we preincubated motoneurons for 2 h with Fas-Fc
(19), an extracellular decoy that competes with interactions be-
tween Fas and FasL, before exposing them to NO donors. Fas-Fc
inhibited the NO-induced phosphorylation of p38 kinase in both
SOD1G93A and SOD1G85R motoneurons by70% (Fig. 1E). These
findings indicate that in both control and mutant SOD1 motoneu-
rons, exogenous NO leads to up-regulation of FasL. However, only
in the presence of G93A or G85Rmutant forms of SOD1 does this
mechanism lead to a Fas-dependent increase in phosphorylation of
p38 kinase.
Functional Evidence for a Role of the NOFas Feedback Loop in Mutant
Motoneuron Death. To confirm that FasL-Fas interactions and p38
activation were functionally involved in NO-triggered death of
mutant SOD1motoneurons, we used dominant-negative constructs
and pharmacological inhibitors.Wepreviously reported that 20M
Detanonoate triggers death of 45% of mutant SOD1G85R and
SOD1G93A motoneurons, whereas it does not affect survival of
motoneurons from C57BL6 mice (6) or SOD1WT mice (Fig. 2E).
To detect potential involvement of Daxx in the NOFas feedback
loop, we electroporated purified SOD1 motoneurons with vectors
encoding either a dominant-negative formofDaxx (Daxx-DN),WT
Daxx, or a control vector. An EGFP vector was coelectroporated to
monitor survival of transducedmotoneurons (Fig. 2A andB). After
administration of 20 M Detanonoate, the survival of SOD1G85R
and SOD1G93A motoneurons transduced with WT Daxx or control
vector was reduced by 42% and 55%, respectively (Fig. 2 C andD).
These figures are close to those for nonelectroporated cells, dem-
onstrating that the transduced neurons are representative of the
whole population. In contrast, expression of Daxx-DN almost
completely protected mutant SOD1G85R and mutant SOD1G93A
motoneurons against NO-induced cell death (Fig. 2 C and D).
Mutant motoneuron death induced by exogenous NO was also
strongly inhibited by Fas-Fc, SB203588, an inhibitor of p38 kinase,
and L-VNIO, an inhibitor of nNOS (Fig. 3 A and B). Thus, in
agreement with the expression data, FasL-Fas interactions, p38
kinase, and nNOS are all required for NO-triggered death.
These results provided strong functional evidence for a feedback
loop triggered by NO in mutant SOD1 motoneurons. However, it
Fig. 1. Regulation of FasL and p38 kinase by NO in cultured motoneurons.
Motoneurons were cultured for 16 h and then treated for 6 or 12 h with the
NO donor Detanonoate (20 M). (A and B) Western blots of SOD1G85R and
SOD1G93A motoneuron protein extracts demonstrated that the 38 kDa form of
FasL protein was strongly up-regulated by NO within 6–12 h. (C) Similar
up-regulation of FasL protein was seen in C57BL6 motoneuron extracts after
Detanonoate addition. Control protein extracts were prepared immediately
before Detanonoate addition (0). Blots were reprobed with an antibody
against neurofilament medium chain (NF-M). (D) Immunocytochemistry re-
vealed a strong increase in phosphorylated p38 kinase in SOD1G93A motoneu-
rons exposed for 6 h to Detanonoate as compared with SOD1G93A motoneu-
rons cultured under basal conditions or motoneurons from C57BL6 mice.
Motoneurons are colabeled with anti MAP-2 antibodies and DAPI. (E) Histo-
grams showing that Detanonoate increased the phospho-p38 immunoreac-
tivity (IR) in mutant SOD1G93A and SOD1G85R motoneurons by 2- and 2.8-fold,
respectively, although having no significant effect on C57BL6 or SOD1WT
motoneurons. Detanonoate-induced phosphorylation of p38 kinase in mu-
tant motoneurons was blocked by preincubation with Fas-Fc. Values for
phospho-p38 kinase IR were normalized to MAP-2 IR; error bars represent
SEM.
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remained possible thatNO from the exogenous donorwas provided
at levels in excess of those generated by the FasNO pathway, and
thereby led to nonphysiological activation of Fas. We therefore
looked for evidence of the feedback loop in neurons triggered to die
by another element of the pathway, the Fas receptor itself. Mutant
SOD1 motoneurons were exposed to agonistic anti-Fas antibodies
in the absence or presence of Fas-Fc (Fig. 3 C and D). Fas-Fc does
not functionally interact with the Fas antibodies used to trigger
death (Fig. 7C). Blockade of FasLFas interactions by Fas-Fc gave
nearly complete protection against cell death (Fig. 3C andD). This
result demonstrates that even when the pathway is triggered by the
endogenous Fas receptor, further activation of Fas by FasL is
required for cell death to occur (Fig. 3E).
FasL Is Up-Regulated in Mutant SOD1 Spinal Cord.Our in vitro results
showed that, to kill a mutant SOD1 motoneuron, Fas or NO need
to trigger a feedback loop. The involvement of such a loop, together
with the requirement for transcriptional up-regulation of nNOS (6)
may explain the relatively slow time course of motoneuron death
when compared with other cellular models of Fas-triggered apo-
ptosis. We reasoned that it might also be related to the late onset
and prolonged time course of the neurodegenerative process in
mutant SOD1 mice in vivo. We therefore asked whether the
elements of the FasNO feedback loop were expressed in the spinal
cord andwhether they showed alterations during the period leading
up to the onset of clinical symptoms.
Fig. 2. Role of Daxx in mutant SOD1 motoneuron death. (A and B) Plasmid
electroporation was used to coexpress a dominant negative FLAG-tagged
form of Daxx (Daxx-DN) and EGFP in cultured motoneurons. (C and D)
SOD1G85R or SOD1G93A motoneurons were electroporated with the EGFP
expression vector in combination with an empty control vector or vectors
encoding either WT Daxx or Daxx-DN. At 1 day in vitro (DIV), motoneurons
from each electroporation were either exposed to the NO donor Detanonoate
or kept under basal conditions. Motoneuron survival at 3 DIV was expressed
as the percentage of EGFP-positive cells in the presence versus absence of NO.
Daxx-DN protected mutant SOD1G85R and SOD1G93A motoneurons from NO-
triggered cell death. Expression of Daxx-WT had no effect on survival. The
differences between the effects of Daxx-DN and Daxx-WT were statistically
significant: P 0.005 for SOD1G85R; P 0.01 for SOD1G93A, Student’s t test. (E)
Survival of SOD1WT motoneurons transduced with control, Daxx-WT, or
Daxx-DN vectors with or without NO challenge. Histograms represent means
and SEM from two independent experiments.
Fig. 3. Role of FasL, Fas, p38 kinase, and nNOS in mutant SOD1 motoneuron
death. (A–D) Mutant SOD1 motoneurons were treated (or not treated) at 1 DIV
with Detanonoate (A and B) or agonistic anti-Fas antibodies (C and D). Cell
survival was quantified at 3 DIV by phase-contrast microscopy and expressed
relative to the number of motoneurons alive under basal conditions (0). Addition
of the extracellular part of Fas receptor, Fas-Fc, the p38 kinase inhibitor SB203580
(5 M), or the nNOS inhibitor L-VNIO (10 M) significantly reduced the NO-
triggered death of SOD1G85R (A) or SOD1G93A (B) motoneurons. Mutant SOD1
motoneuron death mediated by agonistic anti-Fas antibodies at 0.5 ngml or 100
ngml was prevented or significantly reduced by Fas-Fc. Error bars show SEM. *,
P 0.05; **, P 0.01; ***, P 0.001, Student’s t test. (E) Model illustrating the
FasNO feedback loop in mutant SOD1 motoneurons.








Disease course varies between different lines of mutant SOD1
mice: SOD1G93A mice expressing a catalytically active form of
human SOD1 display an early disease onset 100 days of age (4),
whereas SOD1G85R mice express an inactive form of SOD1 leading
to late onset around day 200 (3). We therefore chose to analyze
these mouse lines at comparable presymptomatic stages when the
total number of motoneurons is still normal: day 75 for SOD1G93A
mice and day 120 for SOD1G85R mice (7, 20) (Supporting Materials
and Methods, which is published as supporting information on the
PNAS web site). We found that not only the Fas receptor, as shown
in ref. 21, but also its endogenous ligand FasL and its signaling
intermediate Daxx were expressed in control spinal cord (Fig. 4A).
We therefore quantified the expression of different elements of the
pathway in presymptomatic mutant mice.
In nontransgenic mice, 31 2% of all choline acetyl transferase
(ChAT)-positive motoneurons in the lumbar spinal cord segment
L4 expressed significant levels of FasL at day 75 (n  3 mice) and
29  4% were stained at day 120 (n  2). In SOD1WT mice, the
number of FasL positive motoneurons (26.5  3.2%, n  3) was
close to that in nontransgenic mice. Strikingly, the proportion of
FasL-positive motoneurons was at least two-fold higher in
SOD1G93A mice at 75 days (70  1.9%, n  4) and in SOD1G85R
mice at 120 days (60.2 6.6%, n 4; Fig. 4B; P 0.001, Student’s
t test). We therefore asked whether FasL might be able to engage
Fas receptor signaling in motoneurons in vivo. Double immuno-
fluorescence labeling of presymptomatic SOD1G93A spinal cord
showed that all FasL-positive motoneurons coexpressed significant
levels of Fas (Fig. 4C).
Daxx Accumulates in Nuclear Speckles in Motoneurons of Mutant
SOD1 Mice. Immunostaining for Daxx in control and mutant SOD1
lumbar spinal cords revealed a diffuse cytoplasmic and nuclear
localization in a broad range of neurons in the ventral and dorsal
horn (Figs. 4A and 5A). Interestingly, in motoneurons, Daxx
accumulated in discrete subnuclear domains (Fig. 5B) that stained
positive for sc35, a general splicing factor and marker of nuclear
speckles. Only a subpopulation of nuclear speckles were stained for
Daxx. Colocalization of Daxx and sc35 was confirmed by Z-scan
confocal analysis (data not shown). These nuclear domains (Daxx-
NBs) are reminiscent of promyelocytic leukemia nuclear bodies
(PML-NB) which, in other cell types, have been shown to contain
sc35 (22–24). We quantified Daxx-NBs in control and mutant
SOD1 motoneurons (Fig. 5C). Lumbar motoneurons contained
2.2  0.9 Daxx-NBs and 1.9  1.1 Daxx-NBs per section in
C57BL6 mice aged 75 and 120 days, respectively, and 1.8  1.2
Daxx-NBs per section in SOD1WT mice aged 75 days. In contrast,
the number of Daxx-NBs was increased to 5.5  1.5 per section in
SOD1G93A mice and 3.4 0.2 in SOD1G85R mice (mean SD, n
3, P  0.001, Student’s t test). In conclusion, therefore, two key
intermediates of the FasNO signaling loop, FasL and Daxx, are
activated in motoneurons of presymptomatic ALS mice.
A Dominant-Negative Form of Daxx Inhibits FasL Up-Regulation in
Vivo. To address the functional relevance of Fas-Daxx signaling in
mutant SOD1-linkedmotoneuron disease, we crossbred SOD1G93A
mice with transgenic mice expressing a dominant negative form of
Daxx. TheseDaxx-DNmice (25) show aweaker phenotype than the
Daxx null mutants, which are embryonically lethal (26). Western
blot analysis demonstrated that SOD1 and Daxx-DN transgenes
were expressed in lumbar spinal cord of double transgenic
SOD1G93A;Daxx-DN mice at levels similar to those in the parental
strains (Fig. 5D). Endogenous Daxx expression was not influenced
by Daxx-DN (Fig. 5D). Interestingly, in SOD1G93A;Daxx-DN mice,
only 56.4  3.9% of L4 motoneurons were FasL-positive, as
compared with 70  1.9% in SOD1G93A and 32.6  7.9% in
Daxx-DNmice (mean SD, n 3 each, P 0.001; Fig. 5E). Thus,
expression of Daxx-DN leads to a reduction of 36% in the mutant
SOD1G93A-induced increase in FasL-positive motoneurons. These
data are consistent with a model in which chronic cycling of the
mutant SOD1-dependent Fas feedback loop is required to build up
signaling intermediates to levels at which they can trigger neuro-
degeneration.
Discussion
Amplification mechanisms play an important role in intracellular
signaling pathways. The best studied examples are posttranslational
Fig. 4. Up-regulation of FasL in lumbar motoneurons of mutant SOD1 mice.
(A) Transverse sections of L4 lumbar spinal cords of C57BL6 (control), 75-day-
old SOD1G93A, and 120-day-old SOD1G85R mice immunostained for Fas, Daxx,
FasL, and choline acetyl transferase (ChAT). Fas and Daxx displayed a scattered
expression pattern in various cell types of the gray and white matter. In control
mice, FasL was mainly detected in dorsal and ventral horn neurons, including
a few motoneurons. In SOD1G93A and SOD1G85R mice, a high proportion of
motoneurons, as identified by ChAT staining on adjacent sections, was posi-
tive for FasL. (Scale bar: 100 m.) (B) Histograms showing the percentage of
FasL-positive motoneurons in serial sections of L4 lumbar spinal cord. Note the
increased percentage of FasL-positive motoneurons in SOD1G93A and
SOD1G85R mice as compared with C57BL6 and SOD1WT mice. (C) Immunola-
beling reveals coexpression of FasL and Fas in spinal cord motoneurons in a
75-day-old SOD1G93A mouse. (Scale bar: 50 m.)
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modifications, e.g., protein phosphorylation and proteolysis, but
signal amplification can also be achieved by induction of gene
expression. We previously showed that Fas activation in cultured
motoneurons results in transcriptional up-regulation of nNOS (6).
Here we provide the evidence that this signal needs to be amplified
by a positive feedback loop. In particular, we show that NO is able
to up-regulate FasL, thereby retrogradely inducing Fas signaling. In
mutant SOD1 motoneurons, this feedback loop leads to phosphor-
ylation of p38 kinase and activation of Daxx and nNOS in the
slowest cell death process yet reported downstream of the much-
studied Fas receptor. Several key elements of this loop are activated
in vivo in mutant SOD1 mice. We show that SOD1G93A and
SOD1G85R mice display presymptomatically an increased number
of FasL-positive motoneurons in comparison with control mice, as
well as an increased accumulation of the Fas adaptor protein Daxx
in nuclear bodies.
These findings extend reports concerning early activation of
Ask-1 (16) and of several protein kinases including p38 (refs. 13–15
and 27; C.R., unpublished results) in SOD1G93A mice. Taken
together, these findings provide a molecular means for comparing
the disease process in thesemousemodels of familial ALSwith that
in human patients with sporadic ALS unlinked to SOD1mutations.
Indeed, Bendotti et al. (27) report that sporadic ALS cases show the
same characteristic skein-like staining pattern for phospho-p38 as
that observed in mutant SOD1G93A mice.
A particularly striking aspect of the FasNO feedback loop is that
its activation is absolutely required for motoneuron cell death over
the normal time span of motoneuron cultures. Even triggering the
pathway by using agonistic Fas antibodies does not lead to death
when interactions between FasL and Fas are blocked by using
Fas-Fc. Therefore, the amplification provided by the loop is not
simply a reinforcement mechanism. It is necessary to transform a
subliminal activation of the pathway into an effective death stim-
ulus. This result presumably reflects a low-intensity stimulation of
the death-inducing signaling complex (DISC) complex inmotoneu-
rons compared with thymocytes or hepatocytes, perhaps because
levels of Fas and its signaling intermediates are relatively low in
these cells (12).
One prediction of our data is that blocking the FasNO loop in
mutant SOD1mice should affect disease course. Indeed, inhibition
of Daxx in mutant SOD1G93A mice by transgenic Daxx-DN expres-
sion blocked FasL up-regulation in about one-third of the sensitive
motoneurons. This figure probably underestimates the role of the
FasNO loop because transgenic Daxx-DN mice are hypomorphs
rather than complete nulls (25). The same is true for the majority
of existing mouse mutants in which Fas signaling is still present at
levels sufficient to trigger this loop: Fas knockout mice produce a
truncated Fas protein that conserves part of its intracellular domain
(28, 29) lprmice are regulatorymutants of the Fas gene and express
significant levels of Fas protein (ref. 30; C.R. and B.P., unpublished
data), and gld mice bear a point mutation in FasL that does not
completely inactivate the ligand (31). It will thus be critical to test
the effects of complete inactivation of Fas or FasL on pathological
motoneuron death.
In the past, crossing mutant SOD1 mice with mice carrying a
loss-of-function allele of the nNOS gene did not prolong survival
(32). Nevertheless, the nNOS enzyme can exist in three forms
resulting from alternative splicing (33) and specific increases in the
 and  forms have been reported in spinal cords from sporadic
ALS patients (34). The nNOS mutant mice used for the cross
display residual NOS activity of 15% of control and, strikingly,
produce the same  and  forms of nNOS as those found in ALS
patients (32). In support of our model, administration of the nNOS
inhibitor AR-R 17.477 significantly prolonged the lifespan of
SOD1G93A mutant mice (32). In the future, it will be important to
determine the precise role of NO synthases in this process, because
a requirement for NO also has been demonstrated in death of
Fig. 5. Daxx activation in lumbar motoneurons of mutant SOD1 mice and its
functional relevance in the FasNO loop. (A) Immunolabeling reveals that
Daxx accumulates in the nuclei of motoneurons and forms nuclear bodies.
SOD1G93A,C57BL6 littermates and SOD1WT mice were analyzed at age 75 days;
SOD1G85R and C57BL6 litter mice (C.R., data not shown) were analyzed at age
120 days. (Scale bar: 20 m.) (B) Daxx nuclear bodies (arrows) are associated
with a subpopulation of nuclear speckles, as detected by confocal analysis of
Daxx- and sc35-immunostained SOD1G93A lumbar spinal cords at age 75 days.
(C) The number of Daxx nuclear bodies (Daxx-NBs) in L4 motoneurons was
higher in SOD1G93A and SOD1G85R mice than in C57BL6 or SOD1WT mice of the
same age. Values represent means  SD from three mice per genotype; ***,
P  0.001, Student’s t test. (D and E) Analysis of double transgenic
SOD1G93A;Daxx-DN mice. (D) Western blots of protein extracts from lumbar
spinal cords show that the dominant negative form of Daxx (Daxx-DN) and the
human SOD1G93A are expressed at similar levels in double transgenic mice and
in the parental mice at age 75 days. Daxx-DN was revealed with an anti-FLAG
antibody that also detects a nonspecific (ns) upper band. Daxx-DN expression
did not modify expression of endogenous Daxx because the three known Daxx
isoforms of 70, 97, and 110 kDa (43) were detected at similar levels in all
genotypes. (E) Transgenic Daxx-DN expression significantly reduced the per-
centage of FasL-positive motor neurons in double transgenic mutant
SOD1G93A;Daxx-DN mice as compared with values in age-matched 75-day-old
SOD1G93A mice. Values are means  SD, n  3 per genotype; ***, P  0.001,
one-way ANOVA followed by Newman–Keuls post hoc analysis.








motoneurons induced by avulsion (35) or neurofilament gene
mutations (36).
Feedback amplification loops involving other intermediates in
the Fas signaling, such as caspase-8 and caspase-3 or Bid have been
reported in acellular systems and nonneuronal cells (37, 38). In the
context of ALS, the FasNO feedback loop is of particular interest
because it involves an extracellular step and diffusible factors. The
cell death trigger NO is known to be produced not only by
motoneurons but also by microglia and activated astrocytes (34, 39)
and Fas agonists have been detected in sera of patients with
sporadicALS (40). ‘‘Community effects’’may thus allow for cellular
neighbors to accelerate or to inhibit motoneuron death (5) and also
underlie the clinical finding that ALS often progresses locally,
between adjacent muscles or motor pools. Further studies are
required to better understand the molecular and cellular basis of
these phenomena.
We believe that chronic cycling of feedback loops of the type
described here may provide a general approach to understanding
the delayed onset and relatively slow progression of many neuro-
degenerative diseases. As has been proposed for nucleation of
mutant proteins with polyglutamine expansions (41), the initial
insult produced by the feedback loopmay be subliminal andwithout
phenotype. However, as levels of toxic intermediates and death
signals build up, they may reach a threshold that can trigger the
pathological process. If this model is correct, then therapeutic
intervention at the level of ‘‘death receptors’’ and cell death
pathways should be envisioned at much earlier stages in the disease
process than is generally imagined.
Materials and Methods
See Supporting Materials and Methods for details.
Animals and Reagents. SOD1G85R mice, line 148 (3), were main-
tained as homozygotes, SOD1G93Amice (4) and SOD1WTmice, line
76 (3) as hemizygotes. All mice were on a pure C57BL6 back-
ground. The following reagents and antibodies were used: brain-
derived neurotrophic factor and ciliary neurotrophic factor (R&D
Systems), glial cell line-derived neurotrophic factor, sodium nitro-
prusside (Sigma), Detanonoate, Fas-Fc, L-VNIO (Alexis, San
Diego,), SB203580 (Calbiochem), anti-mouse Fas (JO2, Pharmin-
gen); anti Fas (M-20) and anti FasL (N-20 and N-20-G, Santa Cruz
Biotechnology); anti-FLAG (M2, Sigma), anti-NF-M (Ab1987,
Chemicon), anti-sc35 (S4045, Sigma), anti-phospho-p38 (Cell Sig-
naling Technology, Beverly, MA), anti-MAP2 (Sternberger–
Meyer, Jarrettsville, MD), and secondary antibodies (Jackson
ImmunoResearch or Molecular Probes).
Immunohistochemistry of Spinal Cord. Spinal cord cryosections (16
m) were incubated with primary antibodies [1:100 for anti-FasL,
N-20-G, and anti-Fas, M-20; 1:200 for anti-Daxx, M112; 1:500 for
anti-sc35, S4045, and anti-choline acetyl transferase (ChAT)], re-
vealed with the ABC staining kit (Vector Laboratories) or with
fluorochrome-conjugated secondary antibodies and analyzed by
confocal microscopy. FasL-positive motoneurons or fluorescently
labeled Daxx nuclear bodies were counted on at least 20 different
sections originating from three mice per genotype.
Motoneuron Culture and Analysis.Male transgenic SOD1mice were
mated with female C57BL6 mice, embryos harvested at embry-
onic day 12.5, and genotyped by PCR (6). Motoneurons were
purified from ventral spinal cords by using a metrizamide density
gradient (42), cultured in the presence of neurotrophic factors and
treated at 1 DIV with Detanonoate or anti-Fas antibodies. Elec-
troporationwas done as described (6). Cell survival was determined
by fluorescence or phase-contrast microscopy. Immunohistochem-
istry, quantitative confocal microscopy, and Western blot analysis
were performed as described in Supporting Materials and Methods.
Soluble FasL in conditioned media was measured by ELISA (R &
D Systems). All experiments were performed in triplicate or
quadruplicate and repeated at least twice.
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